Heart artery scans over time in people with inherited high cholesterol
Uses heart artery scans to track plaque in adults with familial hypercholesterolemia.
Plain-language title generated from the registry record
Registry title: "Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)"
Key facts
- Where
- Paris, FranceSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 60 years old?
Source: NCT07427472, who can take part
Where in France
- APHP Hospital Saint-AntoineParis, FranceNot yet recruiting
- APHP-Sorbonne, Pitié Salpêtrière HospitalParis, FranceTaking people
- Plateau d'investigation clinique (PIC) IHU-ICANParis, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07427472
- Record updated
- 24 June 2026
- Original description
This multicenter, non-randomized interventional study aims to assess coronary artery disease progression over 5 years in patients with genetically confirmed heterozygous familial hypercholesterolemia (HeFH), using coronary computed tomography angiography (CCTA).Read full original descriptionShow less
Detection and Longitudinal Follow-up of Non-calcified and Calcified Coronary Lesions in Heterozygous Familial Hypercholesterolemia (DESTINY-FH)
This multicenter, non-randomized interventional study aims to assess coronary artery disease progression over 5 years in patients with genetically confirmed heterozygous familial hypercholesterolemia (HeFH), using coronary computed tomography angiography (CCTA).
The primary endpoint is the visual evaluation of coronary stenosis using CAD-RADS v2.0, identifying changes between baseline (2018-2022) and study inclusion. The study will enroll 300 patients (100 protected, 200 non-protected) from La Pitié-Salpêtrière hospital and Saint Antoine Hospital (Paris). Participation lasts up to one week. Total study duration is 2 years, with extended follow-up through routine care data over 10 years.
Inclusion: Patients with heterozygous familial hypercholesterolemia; Aged 30 to 60 years; Patients who underwent a CAC score and a coronary CT angiogram at least 5 years ago, exclusively at the same imaging center (ICT de la Pitié Salpetrière); Patient asymptomatic for exertional chest pain at the time of CCTA; Clinical examination performed; Beneficiary of a social protection scheme or entitled person (excluding AME); Patient informed and consent form signed.
Exclusion: Simultaneous participation in other interventional research involving the human body, or period of exclusion following previous research involving the human body still in progress; Only for patients who need to undergo a CT angiogram and a thoraco-abdominal-pelvic CT scan:; Renal insufficiency (LC<60); Unbalanced diabetes when acquiring a previous coronary angioscanner; Personal history of cardiovascular disease and myocardial infarction at the time of CCTA; Contraindication to iodinated contrast media; Patient having already had an adverse event (AE) during the acquisition of a prior coronary angioscanner; Patient under guardianship, or unable to give consent; Pregnancy, breast-feeding; Technical contraindication: weight > 250 kg; Adults subject to a legal protection order; Contraindication to esmolol and/or atenolol.